Table 2.
Multivariate analysis of baseline and serial CA features from protocol enrollment
| Variable | N/N (%) | HR (95% CI) | P-value |
|---|---|---|---|
| Overall survival | |||
| CA at baseline | 431/1213 (36) | 7.20 (4.97, 10.44) | <0.001 |
| TT protocols | 875/1213 (72) | 0.57 (0.47, 0.69) | <0.001 |
| Development of CA prior to first transplanta | 3.28 (2.09, 5.15) | <0.001 | |
| Loss of CA prior to first transplanta | 0.38 (0.26, 0.54) | <0.001 | |
| Development of CA after first transplanta | 6.24 (4.68, 8.31) | <0.001 | |
| Loss of CA after first transplanta | 0.63 (0.38, 1.05) | 0.076 | |
| Achieved CRa | 0.93 (0.76, 1.13) | 0.438 | |
| Age≥65 years | 230/1213 (19) | 1.34 (1.06, 1.70) | 0.014 |
| B2M≥3.5 mg l−1 | 237/1213 (20) | 1.52 (1.21, 1.90) | <0.001 |
| Hb<10 g per 100 ml | 306/1213 (25) | 1.43 (1.17, 1.76) | <0.001 |
| IgA isotype | 279/1213 (23) | 1.41 (1.13, 1.75) | 0.002 |
| LDH≥190 U l−1 | 354/1213 (29) | 1.25 (1.01, 1.56) | 0.041 |
| Event-free survival | |||
| CA at baseline | 431/1213 (36) | 3.82 (2.76, 5.30) | <0.001 |
| TT protocols | 875/1213 (72) | 0.65 (0.55, 0.77) | <0.001 |
| Development of CA prior to first transplanta | 2.40 (1.64, 3.51) | <0.001 | |
| Loss of CA prior to first transplanta | 0.46 (0.33, 0.64) | <0.001 | |
| Development of CA after first transplanta | 3.52 (2.58, 4.81) | <0.001 | |
| Loss of CA after first transplanta | 0.78 (0.47, 1.29) | 0.336 | |
| Achieved CRa | 0.66 (0.56, 0.79) | <0.001 | |
| Albumin<3.5 g per 100 ml | 227/1213 (19) | 1.39 (1.14, 1.68) | <0.001 |
| B2M≥3.5 mg l−1 | 237/1213 (20) | 1.45 (1.19, 1.77) | <0.001 |
| CRP≥8 mg l−1 | 5/1213 (0) | 2.84 (1.16, 6.95) | 0.022 |
| IgA isotype | 279/1213 (23) | 1.29 (1.07, 1.55) | 0.008 |
Abbreviations: B2M, β-2-microglobulin; CA, cytogenetic abnormalities; CI, confidence interval; CRP, C-reactive protein; HR, hazard ratio; IgA, immunoglobulin-A; LDH, lactate dehydrogenase; TT, total therapy.
a
Treated as a time-dependent variable.